Nature Communications (Nov 2022)
A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations
- Hui Deng,
- Qian Lei,
- Chengdi Wang,
- Zhoufeng Wang,
- Hai Chen,
- Gang Wang,
- Na Yang,
- Dan Huang,
- Quanwei Yu,
- Mengling Yao,
- Xue Xiao,
- Guonian Zhu,
- Cheng Cheng,
- Yangqian Li,
- Feng Li,
- Panwen Tian,
- Weimin Li
Affiliations
- Hui Deng
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
- Qian Lei
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
- Chengdi Wang
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
- Zhoufeng Wang
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
- Hai Chen
- Targeted Tracer Research and Development Laboratory, Precision Medicine Key Laboratory of Sichuan Province, Precision Medicine Research Center, West China Hospital, Sichuan University
- Gang Wang
- Targeted Tracer Research and Development Laboratory, Precision Medicine Key Laboratory of Sichuan Province, Precision Medicine Research Center, West China Hospital, Sichuan University
- Na Yang
- Targeted Tracer Research and Development Laboratory, Precision Medicine Key Laboratory of Sichuan Province, Precision Medicine Research Center, West China Hospital, Sichuan University
- Dan Huang
- Key Laboratory of Green Chemistry & Technology of Ministry of Education, College of Chemistry, Sichuan University
- Quanwei Yu
- Targeted Tracer Research and Development Laboratory, Precision Medicine Key Laboratory of Sichuan Province, Precision Medicine Research Center, West China Hospital, Sichuan University
- Mengling Yao
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University
- Xue Xiao
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University
- Guonian Zhu
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University
- Cheng Cheng
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University
- Yangqian Li
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University
- Feng Li
- Key Laboratory of Green Chemistry & Technology of Ministry of Education, College of Chemistry, Sichuan University
- Panwen Tian
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
- Weimin Li
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
- DOI
- https://doi.org/10.1038/s41467-022-34627-5
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 19
Abstract
The presence of activating epidermal growth factor receptor (EGFR) mutations in patients with lung cancer correlates to improved response to EGFR-tyrosine kinase inhibitors. Here, the authors present a fluorescence-activated cell sorting assay to identify EGFR mutations with functional activity in patients and demonstrate its utility in predicting response to EGFR-TKI.
